News und Analysen
EQS-News: Evotec SE reports H1 2025 results: Strong progress on strategy execution
EQS-News: Gerresheimer AG: Achim Schalk To Join the Gerresheimer Management Board
2 Magnificent Stocks to Buy That Are Near 52-Week Lows
The S&P 500 has a miserly yield of 1.2%. The average healthcare stock's yield is about 1.8%. Compared to that, Merck's (NYSE: MRK) roughly 4% yield is highly attractive. And LTC Properties' (NYSE:
3 High-Yield Healthcare Stocks to Buy Hand Over Fist in August
If you are looking at healthcare stocks for dividend ideas in August, don't get too caught up on the sector's low 1.8% dividend yield. You can do much better than that without having to take on huge
EQS-News: RHÖN-KLINIKUM AG closes first half of 2025 with solid results
EQS-News: Carl Zeiss Meditec grows revenue and earnings in the first nine months of 2024/25
EQS-News: Evotec SE to announce first half-year results 2025 on 13 August 2025
EQS-News: Gerresheimer to Separate Moulded Glass and Intends to Initiate a Subsequent Sales Process
EQS-Adhoc: Gerresheimer AG to Separate Moulded Glass and Intends to Initiate a Subsequent Sales Process
EQS-News: Biotest AG receives a request from Grifols S.A. to convene an extraordinary general meeting
3 High-Yielding Dividend Stocks That Are Trading Near Their 52-Week Lows
The S&P 500 (SNPINDEX: ^GSPC) is offering investors a tiny yield of just 1.2% today. If you think you are being starved of dividend income, well, that's because you are. But you can do much better
EQS-Adhoc: Bayer Aktiengesellschaft: Bayer upgrades currency-adjusted sales and earnings guidance for 2025 and establishes additional provisions for litigation in the United States
EQS-News: Evotec and Sandoz evolve their strategic partnership and agree on potential sale of Just – Evotec Biologics Toulouse site
EQS-Adhoc: Evotec SE and Sandoz AG planning potential sale of Just – Evotec Biologics Toulouse site
Why Merck Stock Slipped Today
On Tuesday, Merck (NYSE: MRK) wasn't one of the better-performing pharmaceutical stocks. In contrast to certain peers, the company's share price declined following the release of second-quarter
Merck Posts Q2 EPS Beat Revenue Slips
Merck (NYSE:MRK), a leading developer of prescription medicines, vaccines, and animal health products, released its second-quarter 2025 results on July 29, 2025. The most notable news was a beat on
EQS-News: Drägerwerk AG & Co. KGaA: Dräger with strong order intake in the first half of 2025 – Highest demand in five years
Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever
Healthcare stocks aren't exactly known for offering large yields, with the average healthcare stock at just 1.8% or so. You can do better than that and get reliable dividend stocks while you are at
EQS-News: Sartorius continues growth course; earnings rise at a significantly overproportionate rate
EQS-News: Evotec adjusts revenue guidance and confirms profit guidance anticipating a more profitable revenue mix
EQS-Adhoc: Evotec SE adjusts revenue guidance while confirming profit guidance
Does This Move Make Merck Stock a Buy?
Merck (NYSE: MRK), a leading pharmaceutical company, generates consistent revenue and profits. However, the stock has been under pressure over the past year due to its reliance on Keytruda, its
Merck Just Announced a $10 Billion Deal That Will Help Diversify Its Business
One of the biggest concerns with healthcare giant Merck (NYSE: MRK) is its dependence on top-selling cancer drug Keytruda. While it has been a beast for the business over the years, generating
EQS-News: Gerresheimer ends discussions with private equity investors about a potential takeover offer



